Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Daily News

CV Risk Modest for Most Cancer Survivors in Large Danish Registry

L.A. McKeown

June 17, 2025

News Daily News

Dual Approach the Best Remedy for Aortic Stenosis, Amyloidosis: Registry

Caitlin E. Cox

June 09, 2025

News Conference News SCAI 2025

When Early Cardiogenic Shock Isn’t Dealt With, Outcomes Can Suffer

L.A. McKeown

May 09, 2025

News Daily News

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

Caitlin E. Cox

May 06, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Daily News

Intravascular Imaging During PCI Should Be a Performance Metric, Researchers Say

Todd Neale

February 11, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

Advertisement

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

CV Risk Modest for Most Cancer Survivors in Large Danish Registry

Dual Approach the Best Remedy for Aortic Stenosis, Amyloidosis: Registry

When Early Cardiogenic Shock Isn’t Dealt With, Outcomes Can Suffer

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

What’s Going to Be Hot at ACC 2025?

Intravascular Imaging During PCI Should Be a Performance Metric, Researchers Say

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content